• Home
  • About Us
    • About us
    • Scientific Advisory Board
    • People
    • Business Strategy
    • Event Calendar
  • Development
    • Portfolio
    • APTA-1
    • Intellectual property and patent
    • What is sepsis?
  • Market
    • Sepsis
    • Clinical application
  • Investor Relations
    • Company Information
    • Financial Information
    • Largest Shareholders
    • Financial Calendar
    • Presentations
  • News
    • World Sepsis Day
  • Contact
  • en
  • sv
  • Home
  • About Us
    • About us
    • Scientific Advisory Board
    • People
    • Business Strategy
    • Event Calendar
  • Development
    • Portfolio
    • APTA-1
    • Intellectual property and patent
    • What is sepsis?
  • Market
    • Sepsis
    • Clinical application
  • Investor Relations
    • Company Information
    • Financial Information
    • Largest Shareholders
    • Financial Calendar
    • Presentations
  • News
    • World Sepsis Day
  • Contact
  • en
  • sv

Archives

Home / 2019
  0
By Erika Medin
In News
Posted 9 December 2019

Aptahem enters consortium together with Örebro University, AnaMar AB and Dalhousie University

Aptahem (publ) today announced that the company now enters a consortium together with Örebro University, the pharmaceutical development company AnaMar and Dalhousie University in Canada. The [...]

READ MORE
  0
By Erika Medin
In News
Posted 11 October 2019

Aptahem announces strengthened research results with Apta-1 from completed NHP study

Aptahem (publ) today announce positive final results from the exploratory sepsis study with non human primates, the NHP study. The new preclinical results continue to support Apta-1’s [...]

READ MORE
  0
By Erika Medin
In News
Posted 7 October 2019

Aptahem present preclinical progress of the company’s lead candidate Apta-1 at the world’s largest conference for intensive care

Aptahem (publ) announced today that a presentation entitled “Apta-1, a novel RNA aptamer, improves outcome in an animal model of sepsis” will be held at the World Congress of [...]

READ MORE
  0
By Erika Medin
In News
Posted 4 July 2019

Aptahem signs agreement with new contract manufacturer

Aptahem (publ) announced today that the company has signed an agreement with a GMP-certified (Good Manufacturing Practice) contract manufacturer, LGC Group. LGC Group will manufacture the [...]

READ MORE
  0
By Erika Medin
In News
Posted 11 June 2019

Aptahem’s cooperation with Seattle Children’s Hospital increases the understanding of Apta-1

Aptahem (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are [...]

READ MORE
  0
By Erika Medin
In News
Posted 11 April 2019

Aptahems latest patent application is published

Aptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe [...]

READ MORE
  0
By Erika Medin
In News
Posted 12 March 2019

Aptahem confirms CMO Dr. Bylock’s responsibilities

Aptahem (publ) announced today that Dr. Anders Bylock, Chief Medical Officer (CMO), is taking on another part-time position effective immediately. Dr Bylock engagement with the company as CMO as [...]

READ MORE
  0
By Erika Medin
In News
Posted 8 February 2019

Aptahem reports delay in delivery of its drug product

Aptahem (publ) announced today that manufacture of its drug product has been delayed as a result of technical challenges. As a consequence, Aptahem anticipates that commencement of the planned [...]

READ MORE
  0
By Erika Medin
In News
Posted 21 January 2019

Aptahem recalls outstanding convertible notes to Yorkville

Aptahem AB (publ) today announces that the company intends to recall the outstanding amount of convertible notes held by YA II PN Ltd, a fund represented by the U.S.-based Yorkville Advisors [...]

READ MORE
  0
By Erika Medin
In News
Posted 4 January 2019

Endpoints News article: Aptahem – a Swedish biotech aiming to win the race against sepsis

In the fight to save a person affected by sepsis every second counts – each hour that passes increases the risk of death with 8 percent. It is literally a race against time, a race that the [...]

READ MORE
Contact



Norra Vallgatan 58, 4 TR
211 22 Malmö
Sweden
E-mail: info@aptahem.com

Aptahem is supporting Global Sepsis Alliance
To all salesmen:

We kindly decline all direct contact with salesmen of different types of products and services.

Copyright All Rights Reserved © 2016

Start typing and press Enter to search